Pharmaceuticals

Osteoporosis Drugs Industry Forecast to Hit $14.2 Billion by 2029 With a Strong 2.5% CAGR

November 10, 2025 by Marketing Posting

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Are The Growth Projections For The Osteoporosis Drugs Market Size During 2025–2029?

The osteoporosis drugs market has demonstrated consistent expansion in recent years. It is projected to increase from $12.48 billion in 2024 to $12.85 billion in 2025, achieving a compound annual growth rate (CAGR) of 3.0%. The historical growth of this market can be attributed to an aging population, improved awareness and diagnosis, various lifestyle factors, as well as government initiatives and healthcare policies.

The osteoporosis drugs market size is projected to experience consistent expansion over the upcoming years. By 2029, it is anticipated to reach “$14.2 billion, exhibiting a compound annual growth rate (CAGR) of 2.5%. This growth during the forecast period is primarily driven by factors such as the ongoing trend of an aging population, improvements in available treatment options, a heightened emphasis on bone health for men, enhanced patient education and empowerment initiatives, and supportive global health policies alongside broader insurance coverage. Key trends expected within this period encompass personalized medicine approaches, the investigation of combination therapies, a strong emphasis on strategies for preventing fractures, significant research and development investments into new drug targets, and strategic collaborations aimed at drug development.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9102&type=smp

What Are The Drivers Pushing New Developments In The Osteoporosis Drugs Market?

The increased occurrence of osteoporosis is anticipated to boost the expansion of the osteoporosis drug market. This bone condition arises when there is a reduction in bone mineral density and mass, or alterations in bone quality and structure. Individuals with insufficient calcium intake face a higher risk of developing osteoporosis. The medications for this condition work by enhancing bone mineral density and aiding in fracture prevention. For example, data from June 2024, provided by the Australian Institute of Health and Welfare Australia-Government agency, indicates that in 2022, osteoporosis was responsible for 2,659 deaths, equating to 10.2 deaths per 100,000 population, which constitutes 1.4% of all fatalities. Consequently, the rising incidence of osteoporosis is fueling the growth within the osteoporosis drug market.

Which Key Segments Fueling The Osteoporosis Drugs Market?

The osteoporosis drugs market covered in this report is segmented –

1) By Type: Bisphosphonates, Selective Estrogen Receptor Modulators (SERMs), RANK Ligand Inhibitors

2) By Administration: Oral, Injectable

3) By Distribution Channel: Retail Pharmacies, Hospital Pharmacies, Online Sales

4) By Application: Primary Osteoporosis, Secondary Osteoporosis

Subsegments:

1) By Bisphosphonates: Alendronate, Risedronate, Ibandronate, Zoledronic Acid

2) By Selective Estrogen Receptor Modulators (SERMs): Raloxifene, Bazedoxifene

3) By RANK Ligand Inhibitors: Denosumab

Which Ongoing Trends Are Expected To Shape The Osteoporosis Drugs Market Outlook?

Major companies operating in the osteoporosis drugs market are increasingly embracing innovative solutions. For instance, in November 2023, Apotex Inc., a Canada-based pharmaceutical corporation, introduced Teriparatide Injectable for Osteoporosis Treatment. This teriparatide injection is provided as a pre-filled pen containing 250 mcg/mL, capable of delivering 28 daily doses of 20 mcg per pen, and is intended for single-patient application. This offering will provide patients with essential, cost-effective access.

Which Major Industry Participants Are Leading The Osteoporosis Drugs Market Growth?

Major companies operating in the osteoporosis drugs market include Pfizer Inc., F. Hoffmann La Roche Ltd., Merck & Co Inc., Novartis AG, Bristol Myers Squibb Company, GlaxoSmithKline PLC, Eli Lilly and Company, Amgen Inc., Novo Nordisk A/S, Asahi Kasei Pharma Corporation, Viatris Inc., Teva Pharmaceutical Industries Ltd, Mylan N.V., Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Ltd., Ipsen, Kyowa Kirin Co Ltd., Dr. Reddy’s Laboratories Ltd., Cipla Limited, Recordati S.p.A., Cadila Healthcare Ltd., Lupin Limited, Torrent Pharmaceuticals Ltd., Sunovion Pharmaceuticals Inc., Theramex, Radius Health Inc., Strides Pharma Science Limited, Apotex Inc.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/osteoporosis-drugs-global-market-report

What Are The Key Regional Factors Influencing The Osteoporosis Drugs Market Growth?

North America was the largest region in the osteoporosis market in 2024. The regions covered in the osteoporosis drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Osteoporosis Drugs Market Report:

https://www.thebusinessresearchcompany.com/customise?id=9102&type=smp

Browse Through More Reports Similar to the Global Osteoporosis Drugs Market 2025, By The Business Research Company

Cardiovascular Devices Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cardiovascular-devices-global-market-report

Cardiovascular Surgery Devices And Equipment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cardiovascular-surgery-devices-and-equipment-global-market-report

Spinal Surgery Devices And Equipment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/spinal-surgery-devices-and-equipment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795